Mast Out® (an intramammary infusion product containing Nisin) is under development as an alternative to traditional antibiotics for the treatment of mastitis in lactating cows. The safety profile of Nisin may allow for the use of Mast Out® in the U.S. without milk discard or meat withhold requirements.
In addition, we are exploring product line enhancements to First Defense®, such as claims to prevent scours caused by additional enteric pathogens. In the second quarter of 2009, we entered into an exclusive technology license after achieving proof of concept in studies using this enabling technology against scours covered by rotavirus.
While we continue to pursue internally funded product development programs, we remain interested in acquiring new products and technologies that fit within our sales focus on the dairy and beef industries.